Drug Trial Radar · NCT06119581
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,264
Planned (sponsor's estimate)
Start
Dec 21, 2023
Primary completion
Nov 2027
Study completion Jan 2031
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Nov 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Conditions
- Carcinoma, Non-Small-Cell Lung
- Neoplasm Metastasis
Interventions
LY3537982Drug
Administered orally.
PembrolizumabDrug
Administered IV.
PlaceboDrug
Administered orally.
CisplatinDrug
Administered IV.
CarboplatinDrug
Administered IV.
PemetrexedDrug
Administered IV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE)Time frame: Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)
- Part A and Part B: Progression-Free Survival (PFS)Time frame: Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)
Locations
415 sites in 29 countries. Site status is shown where the registry gives one.
Clearview Cancer Institute
Huntsville, Alabama · Recruiting
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
Banner University Medical Center Phoenix
Phoenix, Arizona · Recruiting
The University of Arizona Cancer Center - North Campus
Tucson, Arizona · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
Cedars-Sinai Medical Center
Los Angeles, California · Recruiting
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California · Completed
BASS Cancer Center
Walnut Creek, California · Recruiting
USO - Rocky Mountain Cancer Centers
Lone Tree, Colorado · Recruiting
Yale University School of Medicine
New Haven, Connecticut · Recruiting
Sibley Memorial Hospital
Washington D.C., District of Columbia · Recruiting
Millennium Oncology Research Clinic
Hollywood, Florida · Recruiting
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida · Recruiting
Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala
Ocala, Florida · Recruiting
Orlando Health Cancer Institute
Orlando, Florida · Recruiting
Comprehensive Hematology Oncology
St. Petersburg, Florida · Recruiting
University Cancer & Blood Center, LLC
Athens, Georgia · Recruiting
Emory University School of Medicine- Grady Campus
Atlanta, Georgia · Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia · Recruiting
University of Illinois at Chicago
Chicago, Illinois · Recruiting
University of Chicago Hospital
Chicago, Illinois · Recruiting
Springfield Clinic Main Campus
Springfield, Illinois · Recruiting
Parkview Research Center at Parkview Regional Medical Center
Fort Wayne, Indiana · Recruiting
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana · Recruiting
Franciscan Health
Indianapolis, Indiana · Recruiting
Community Cancer Center North
Indianapolis, Indiana · Recruiting
The University of Kansas Cancer Center - Westwood
Westwood, Kansas · Recruiting
University of Kentucky Chandler Medical Center
Lexington, Kentucky · Recruiting
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana · Recruiting
Johns Hopkins Bayview Medical Center
Baltimore, Maryland · Recruiting
USO - Maryland Oncology Hematology
Columbia, Maryland · Recruiting
Boston Medical Center
Boston, Massachusetts · Recruiting
Lahey Hospital & Medical Center
Burlington, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
The Cancer & Hematology Centers
Grand Rapids, Michigan · Recruiting
Allina Health Cancer Institute - Abbott Northwestern Hospital
Minneapolis, Minnesota · Recruiting
HealthPartners Cancer Research Center
Saint Paul, Minnesota · Recruiting
North Mississippi Hematology and Oncology Associates
Tupelo, Mississippi · Recruiting
Oncology Hematology Associates
Springfield, Missouri · Recruiting
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada · Recruiting
Showing 40 of 415 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.